Cargando…

Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells

Testing new ways to identify untapped opportunities for glioblastoma therapies remains highly significant. Amplification and overexpression of MDM2 gene is frequent in glioblastoma and disrupting the MDM2−p53 interaction is a promising strategy to treat the cancer. RG7112 is the first-in class inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Her, Nam-Gu, Oh, Jeong-Woo, Oh, Yun Jeong, Han, Suji, Cho, Hee Jin, Lee, Yeri, Ryu, Gyu Ha, Nam, Do-Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052082/ https://www.ncbi.nlm.nih.gov/pubmed/30022047 http://dx.doi.org/10.1038/s41419-018-0825-1

Ejemplares similares

The Protein Neddylation Inhibitor MLN4924 Suppresses Patient-Derived Glioblastoma Cells via Inhibition of ERK and AKT Signaling
por: Han, Suji, et al.
Publicado: (2019)

AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

High-Content Analysis-Based Sensitivity Prediction and Novel Therapeutics Screening for c-Met-Addicted Glioblastoma
por: Oh, Jeong-Woo, et al.
Publicado: (2021)

Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
por: Gluck, W. Larry, et al.
Publicado: (2019)

An Aurora kinase inhibitor, AMG900, inhibits glioblastoma cell proliferation by disrupting mitotic progression
por: Ryu, Jaewook, et al.
Publicado: (2018)

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
por: Moschos, Stergios J., et al.
Publicado: (2022)

Evaluation of AMG 076, a potent and selective MCHR1 antagonist, in rodent and primate obesity models
por: Motani, Alykhan S, et al.
Publicado: (2013)

High-Dose Compound Heat Map for 3D-Cultured Glioblastoma Multiforme Cells in a Micropillar and Microwell Chip Platform
por: Lee, Dong Woo, et al.
Publicado: (2017)

EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor
por: Xu, C, et al.
Publicado: (2014)

NTRK1 Fusion in Glioblastoma Multiforme
por: Kim, Jinkuk, et al.
Publicado: (2014)

WNT Signaling as a Therapeutic Target for Glioblastoma
por: Latour, Michael, et al.
Publicado: (2021)

Comparison of AMG 416 and cinacalcet in rodent models of uremia
por: Walter, Sarah, et al.
Publicado: (2014)

Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness
por: Woo, Seon Rang, et al.
Publicado: (2015)

AMG2850, a potent and selective TRPM8 antagonist, is not effective in rat models of inflammatory mechanical hypersensitivity and neuropathic tactile allodynia
por: Lehto, Sonya G., et al.
Publicado: (2015)

Hydrophilic Glycoproteins of an Edible Green Alga Capsosiphon fulvescens Prevent Aging-Induced Spatial Memory Impairment by Suppressing GSK-3β-Mediated ER Stress in Dorsal Hippocampus
por: Oh, Jeong Hwan, et al.
Publicado: (2019)

Artificial Macrocycles as Potent p53–MDM2 Inhibitors
por: Estrada-Ortiz, Natalia, et al.
Publicado: (2017)

Health Tract, No. 232: Sordid
Publicado: (1865)

Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma
por: Choi, Seung Won, et al.
Publicado: (2021)

Secretome analysis of patient-derived GBM tumor spheres identifies midkine as a potent therapeutic target
por: Han, Suji, et al.
Publicado: (2019)

Correction: Secretome analysis of patient-derived GBM tumorspheres identifies midkine as a potent therapeutic target
por: Han, Suji, et al.
Publicado: (2020)

Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma
por: Sa, Jason K., et al.
Publicado: (2020)

Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer
por: Liontos, Michalis, et al.
Publicado: (2014)

Effect of Severe Renal Impairment on the Safety, Tolerability, and Pharmacokinetics of AMG 986
por: Trivedi, Ashit, et al.
Publicado: (2022)

MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy
por: Miles, Xanthene, et al.
Publicado: (2021)

FcγRIIB-I232T polymorphic change allosterically suppresses ligand binding
por: Hu, Wei, et al.
Publicado: (2019)

mRNA Display Selection of an Optimized MDM2-Binding Peptide That Potently Inhibits MDM2-p53 Interaction
por: Shiheido, Hirokazu, et al.
Publicado: (2011)

A lignan from Alnus japonica inhibits glioblastoma tumorspheres by suppression of FOXM1
por: Shim, Jin-Kyoung, et al.
Publicado: (2022)

Whole genome sequence analysis links chromothripsis to EGFR, MDM2, MDM4, and CDK4 amplification in glioblastoma
por: Furgason, John M., et al.
Publicado: (2015)

Messe in h-moll, BWV 232
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1984)

Mass in B minor, BWV 232
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1992)

Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain
por: Lee, Se Jeong, et al.
Publicado: (2015)

The beta-decay scheme of /sup 232/Fr and the K=0 ground-state band in /sup 232/Ra
por: Peräjärvi, K, et al.
Publicado: (2004)

Phase 1 Concentration‐QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRT‐232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia
por: Taylor, Adekemi, et al.
Publicado: (2021)

E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors
por: Lubner, Sam, et al.
Publicado: (2018)

Structure basis for the modulation of CXC chemokine receptor 3 by antagonist AMG487
por: Jiao, Haizhan, et al.
Publicado: (2023)

Azathioprine antagonizes aberrantly elevated lipid metabolism and induces apoptosis in glioblastoma
por: Nam, Hye Jin, et al.
Publicado: (2021)

HIV-1 Tat potently stabilises Mdm2 and enhances viral replication
por: Raja, Rameez, et al.
Publicado: (2017)

Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma
por: Ananthapadmanabhan, Varsha, et al.
Publicado: (2022)

MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation
por: Pellot Ortiz, Karolina I., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_krsg7ttl0j1ojo41382706ibhs